Predictive value of T-cell subset derangements in lung cancer.
The proportions of T-lymphocytes, T-lymphocyte subsets, NK cells, DR determinant and interleukin-2 receptor-bearing T-lymphocytes were enumerated in 39 patients with lung cancer prior to any chemotherapy. T-lymphocytes, suppressor/cytotoxic T-cells and interleukin-2 receptor-bearing T-cells were found to be significantly higher in patients responding than in those not responding to chemotherapy. Such mononuclear cell subset analysis by monoclonal antibodies might be additional information to consider before undertaking treatment.
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D018288:Carcinoma, Small Cell / Q000188:drug therapy / Q000276:immunology*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy / Q000276:immunology*; D005260:Female; D006684:HLA-DR Antigens; D000949:Histocompatibility Antigens Class II / Q000032:analysis; D006801:Humans; D007376:Interleukin-2 / Q000032:analysis; D007694:Killer Cells, Natural / Q000276:immunology; D008175:Lung Neoplasms / Q000188:drug therapy / Q000276:immunology*; D008297:Male; D013601:T-Lymphocytes / Q000145:classification* / Q000276:immunology; D050378:T-Lymphocytes, Regulatory / Q000276:immunology
D006684:HLA-DR Antigens; D000949:Histocompatibility Antigens Class II; D007376:Interleukin-2